LAUSR

Background: The quality of COVID-19 preprints should be considered with great care, as their contents can influence public policy. Efforts to improve preprint quality have mostly focused on introducing quick peer review, but surprisingly little has been done to calibrate the public’s evaluation of preprints and their contents. The PRECHECK project aimed to generate a tool to teach and guide scientifically literate non-experts to critically evaluate preprints, on COVID-19 and beyond. Methods: To create a checklist, we applied a four-step procedure consisting of an initial internal review, an external review by a pool of experts (methodologists, meta-researchers/experts on preprints, journal editors, and science journalists), a final internal review, and an implementation stage. For the external review step, experts rated the relevance of each element of the checklist on five-point Likert scales, and provided written feedback. After each internal review round, we applied the checklist on a set of high-quality preprints from an online list of milestone research works on COVID-19 and low-quality preprints, which were eventually retracted, to verify whether the checklist can discriminate between the two categories. Results: At the external review step, 26 of the 54 contacted experts responded. The final checklist contained four elements (Research question, study type, transparency and integrity, and limitations), with ‘superficial’ and ‘deep’ levels for evaluation. When using both levels of evaluation, the checklist was effective at discriminating high- from low-quality preprints. Its usability was confirmed in workshops with our target audience: Bachelors students in Psychology and Medicine, and science journalists. Conclusions: We created a simple, easy-to-use tool for helping scientifically literate non-experts navigate preprints with a critical mind. We believe that our checklist has great potential to help guide decisions about the quality of preprints on COVID-19 in our target audience and that this extends beyond COVID-19.